XTL Biopharmaceuticals Ltd ADR (XTLB)

XTL Biopharmaceuticals Ltd ADR (XTLB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $4.6M; returns 1 day +2.5%, 1 week +3.1%, 1 year -59.3%.

XTL Biopharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on acquiring and developing therapeutics for autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for treating systemic lupus erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide. XTL also holds an intellectual property portfolio related to hCDR1.

Groups XTLB belongs to

• Biotechnology
• Biopharmaceutical
• Recent Reverse Splits
• Israel Companies
• Healthcare
• Israel
• Autoimmune Diseases
• Clinical Stage Biotech
• Neuroscience
• Clinical Stage
• Neurological Disorders

XTLB financial model: income statement, cash flow and balance sheet